Camrelizumab, apatinib and hepatic artery infusion chemotherapy combined with microwave ablation for advanced hepatocellular carcinoma

Table 4 Complications comparison related to camrelizumab plus apatinib and hepatic artery infusion chemotherapy or camrelizumab plus apatinib and hepatic artery infusion chemotherapy-microwave ablation

Complications	TRIPLET alone group (n = 122)	TRIPLET-MWA group (n = 95)	P value
Major complications	6 (4.9)	5 (5.3)	1.000
Peritoneal effusion	1 (0.8)	-
Liver abscess	3 (2.5)	1 (1.1)
Biliary fistula	1 (0.8)	-
Biloma	-	2 (2.0)
Hydropneumothorax requiring drainage	-	-
Massive ascites	1 (0.8)	1 (1.1)
Seeding	-	1 (1.1)
Minor complications	36 (29.5)	22 (23.2)	0.755
Liver dysfunction	18 (14.8)	12 (12.6)
Fever	18 (14.8)	10 (10.5)
Abdominal nonspecific pain	3 (2.4)	1 (1.1)
Bile duct dilatation	1 (0.8)	2 (2.0)
Hemorrhage	5 (4.0)	3 (3.2)
Mild pleural effusion	10 (8.1)	-
Mild ascites	6 (4.8)	3 (3.2)
Jaundice	4 (3.2)	3 (3.2)
Other	7 (5.7)	4 (4.0)

Unless otherwise indicated, data are number of patients. Data in parentheses are percentages and were calculated by using the total number of patients in each group as the denominator. TRIPLET: Camrelizumab plus apatinib and hepatic artery infusion chemotherapy; MWA: Microwave ablation.